<div id="readability-page-1"><p>Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Get Free Report) have earned a consensus rating of &#34;Moderate Buy&#34; from the ten research firms that are  covering the stock, Marketbeat Ratings reports. Four research analysts have rated the stock with a hold rating and six have issued  a buy rating on  the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $41.44.</p><ul><li>Want Diversified Upside in Biotechnology? Check out LABU</li></ul><p>A number of equities research analysts have issued reports on the company. Royal Bank of Canada  reissued an &#34;outperform&#34; rating and set a $42.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, February 11th. Chardan Capital  reissued a &#34;buy&#34; rating and set a $60.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, February 11th. B. Riley  restated a &#34;buy&#34; rating and issued a $38.00 price target (down previously from $51.00) on shares of Arrowhead Pharmaceuticals in a report on Friday, February 14th. Finally, HC Wainwright  reiterated a &#34;buy&#34; rating and set a $80.00 price objective on shares of Arrowhead Pharmaceuticals in a research note on Wednesday, February 12th.</p><p><b>Read Our Latest Research Report on Arrowhead Pharmaceuticals</b></p><h2>Insider Activity at Arrowhead Pharmaceuticals</h2><p>In other news, CEO Christopher Richard Anzalone sold 50,800 shares of the company's stock in a transaction dated Friday, April 11th. The shares were sold at an average price of $11.49, for a total value of $583,692.00. Following the sale, the chief executive officer now owns 3,921,255 shares of the company's stock, valued at approximately $45,055,219.95. This represents a 1.28 % decrease in their position. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available through the SEC website. Over the last 90 days, insiders sold 276,839 shares of company stock worth $4,054,176. Company insiders own  4.30% of the company's stock. </p><h2>Hedge Funds Weigh In On Arrowhead Pharmaceuticals</h2><p>Institutional investors and hedge funds have recently added to or reduced their stakes in the company. R Squared Ltd acquired a new position in shares of  Arrowhead Pharmaceuticals in the 4th quarter worth approximately $38,000.  GAMMA Investing LLC raised its position in  Arrowhead Pharmaceuticals by 297.6% in the 1st quarter. GAMMA Investing LLC now owns 2,175 shares of the biotechnology company's stock valued at $28,000 after purchasing an additional 1,628 shares during the last quarter.  GF Fund Management CO. LTD. acquired a new position in  Arrowhead Pharmaceuticals in the fourth quarter worth $49,000.  Van ECK Associates Corp grew its holdings in shares of  Arrowhead Pharmaceuticals by 72.3% during the fourth quarter. Van ECK Associates Corp now owns 2,978 shares of the biotechnology company's stock worth $56,000 after purchasing an additional 1,250 shares during the last quarter.  Finally, KBC Group NV increased its stake in shares of  Arrowhead Pharmaceuticals by 45.9% in the fourth quarter. KBC Group NV now owns 5,224 shares of the biotechnology company's stock valued at $98,000 after buying an additional 1,644 shares in the last quarter. 62.61% of the stock is currently owned by institutional investors and hedge funds. </p><h2>Arrowhead Pharmaceuticals Stock Down 1.0 %</h2><p>ARWR opened at $11.24 on Monday. Arrowhead Pharmaceuticals has a 12 month low of $9.57 and a 12 month high of $30.41. The business has a 50-day moving average of $15.25 and a two-hundred day moving average of $18.59. The company has a debt-to-equity ratio of 7.27, a current ratio of 6.09 and a quick ratio of 6.09. The stock has a market capitalization of $1.54 billion, a price-to-earnings ratio of -2.17 and a beta of 0.99. </p><p>Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last issued its quarterly earnings results on Monday, February 10th. The biotechnology company reported ($1.39) EPS for the quarter, missing the consensus estimate of ($0.42) by ($0.97).  On average, research analysts expect that  Arrowhead Pharmaceuticals will post -2.42 earnings per share for the current year. </p><h2>About Arrowhead Pharmaceuticals</h2> (Get Free Report<p>Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than Arrowhead Pharmaceuticals</li><li>What Does a Stock Split Mean? </li><li>With a 60%+ Upside, There’s Plenty to Love About Lovesac</li><li>Why Are Stock Sectors Important to Successful Investing?</li><li>J.B. Hunt Transport Overcorrects Into a Buying Opportunity</li><li>What to Know About Investing in Penny Stocks</li><li>AppLovin: Can Record Profits Overcome Market Skepticism?</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVJXUg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="600" height="385" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVJXUg"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Arrowhead Pharmaceuticals Right Now?</h2><p>Before you consider Arrowhead Pharmaceuticals, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arrowhead Pharmaceuticals wasn't on the list.</p><p>While Arrowhead Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

ARWR

<p>Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) has received a consensus rating of "Moderate Buy" from ten research firms. Four analysts rated it as hold, while six issued buy ratings. The average price target is $41.44. Recent reports include a $42 target from Royal Bank of Canada and a $60 target from Chardan Capital. The stock is currently down 1.0%, trading at $11.24, with a 12-month range of $9.57 to $30.41. The company reported a quarterly EPS of ($1.39), missing estimates by ($0.97).</p>

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Given Average Rating of "Moderate Buy" by Brokerages